Future Market Insights, Inc.

Asia Pacific Non-Small Cell Lung Cancer Market should grow at 6.7% in the assessment period of 2023-2033. Europe is expected to expand at a CAGR between 7% and 8% during the assessment period 2023-2033. Non-small cell lung cancer will be the fastest growing segment.

NEWARK, Del., Dec. 29, 2022 (GLOBE NEWSWIRE). — According to a recently published study, FMI anticipates that the global population will reach 1.3 billion by 2022. Non-small cell lung cancer market To increase at a 7.2% CAGR between 2023 and 2033. The market is expected to be valued at US$ 20 billion by the end of this assessment period. This industry has seen remarkable growth between 2018 and 2022. The value CAGR was 6.7% and the market closed at US$10 billion. An increase in the number of cases of non-small-cell lung cancer and increased knowledge among patients may have contributed to the market’s expansion.

Non-small-cell lung cancer is one of the most prevalent types of lung cancer. It reduces the lungs’ ability to deliver oxygen to the blood. The majority of lung cancer cases in the world are non-small-cell lung cancer. It accounts for between 80 and 85%. These include passive smoking, active smokers, drinking polluted waters, and being exposed air pollution. There are many treatments available, such as targeted therapy, immunotherapy and other.

Request a Sample https://www.futuremarketinsights.com/reports/sample/rep-gb-16143

Excessive tobacco consumption and passive smoking are the main causes of non-small-cell lung cancer. Long-term exposure to air pollution promotes non-small-cell lung cancer. The existence of large businesses and the entry into the market of vital players will lead to excessive market competition. This will slow down the expansion rate of the lung cancer treatment market.

The high cost of treatment or therapy will limit expansion. North America is the market leader in non-small cell lung disease. This is due to the availability of high-quality healthcare infrastructure, better research and development capabilities by pharmaceutical companies, as well as rapid adoption of new healthcare technology. Asia-Pacific is expected to experience the highest growth rate during the projection period. This is due to the increased spending on healthcare infrastructure, the increasing incidence of non-small-cell lung cancer, and the growing number of seniors who are more sensitive to it.

The Market Study: Key Takeaways

• FMI predicts that the global non-small-cell lung cancer market will grow at 7.2% CAGR between 2033 and 2033.

• The market for non-small-cell lung cancer is valued at US$ 10 billion

• The market for non-small-cell lung cancer worldwide will reach a value of US$20 Billion

• North America is predicted to be the most lucrative region for non-small cell lung carcinoma market growth.

• Future Market Insights projects that Asia Pacific will grow at 6.7% per year during the 2023-2033 period.

• Europe is projected to grow at a CAGR 7% over the assessment period 2023-2033.

• For the period 2023-2033, the largest market share in non-small cell lung carcinoma is expected to be held by chemotherapy.

“Rising investment in research & development efforts by the key players will fuel market expansion even more,” says an analyst at FMI

Receive an exclusive discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16143

Market Competition

Novartis Pharmaceuticals and Merck KGaA are the key players in non-small-cell lung cancer. Eli Lilly and Company is Hoffmann-La Roche and Xcovery. BeyondSpring Pharmaceuticals and OSE Immunotherapeutics are also important.

Recent Developments

• In December 2022 Pluvicto®, a targeted radioligand treatment, has been authorised by the European Commission (EC), according to Novartis. Pluvicto® is licensed for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer in conjunction with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition (mCRPC). These patients were treated with taxane-based chemotherapy and an AR pathway inhibitor.

Get more insights

Future Market Insights’ new offering presents an objective analysis of the global nonsmall cell lung cancer market. It includes historical analysis from 2018-2022 as well as forecast statistics for 2023-2033.

The study reveals essential insights on the basis of Cancer Type Squamous Cell Carcinoma, Adenocarcinoma and Large-cell Carcinoma, by Treatment (Chemotherapy, Targeted Therapy and Immunotherapy), across five major regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).

Get Customization https://www.futuremarketinsights.com/customization-available/rep-gb-16143

In the Non-Small Cell Lung Cancer Industry Survey, Key Segments were Profiled

Non-Small Cell Cancer Market by Cancer Type

• Squamous Cell Carcinoma

• Adenocarcinoma

• Carcinoma Large-cell

Market for Non-Small Cell Lung Cancer Treatment:

• Chemotherapy

• Targeted therapy

• Immunotherapy

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. 1.5.

2. Market Overview

2.1. 2.1.

2.2. 2.2.

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. 3.1.2.

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

See the full report @ https://www.futuremarketinsights.com/reports/non-small-cell-lung-cancer-market

Future Market Insights: Healthcare

The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. Over 100+ reports and more than 1 million data points have been used to analyze the industry in 50+ countries over the past decade. The team provides an overview of key trends such as the competitive landscape and profit margins, as well as research development efforts.

Take a look at Related Research Reports on Healthcare Domain:

Orthopedic Braces and Support Market Size: The market for orthopedic braces, support and other products in the world is estimated to be worth US$ 4.09 Bn (38.6%) by 2022.

Manual Resuscitator Market Trends: Over the forecast period 2022-2030, the global manual resuscitator industry is expected to grow at 5.7% CAGR. The revenue from manual resuscitators sales is expected to reach US$ 543.3 million in 2022, and rise to US$ 8455.3 Mn by 2030.

Compression Therapy Market Growth: The global compression therapy marketis set to record a market value of US$ 3.01 Bn in 2022 and reachUS$ 4.59 Bn by 2030, expanding at a CAGR of 5.4%, which indicates steady positive market growth for the forecast period (2022-2030).

Patient Identification Wristbands Market OutlookThe global patient identification wristbands market will experience a 7.9% CAGR between 2022 and 2030. It is estimated that the market value for this product is approximately US$ 460.3 Million as of 2022.

Medical Nitroglycerin Sprays Market ForecastThe global market for medical nitroglycerin sprays is expected to grow at 4.2% CAGR from US$ 106.3 million in 2022 to US$ 14.7 Mn by 2030.

Our Company:

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. We are the clients of 80% percent of the Forbes 1000 largest enterprises. We serve global clients across all leading & niche market segments across all major industries.

Get in touch with us

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401 Newark, Delaware – 19713, USA
T: +1-845-579-5705
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: [email protected]